Skip to main content

Table 7 Trials of mTOR inhibitors in metastatic breast cancer

From: Antiangiogenic therapy for breast cancer

Reference

Phase

Number of patients

Treatment

Response (%)

PFS (months)

mTOR inhibitor monotherapy

   Chan et al. [78]

II (randomised)

109

Temsirolimus (two dose levels)

ORR 9

NR

   Ellard et al. [79]

II (randomised)

49 (33: daily schedule)

Everolimus (two different schedules)

ORR 12 (daily schedule)

NR

   

ORR 0 (weekly schedule)

NR

NR

mTOR inhibitor plus chemotherapy

   Moulder et al. [81]*

I

15

Everolimus + docetaxel

RR 0

NR

   Mayer et al. [82]

Ib

16

Everolimus + cisplatin + paclitaxel

RR 23

NR

mTOR inhibitor plus endocrine therapy

   Carpenter et al. [83]

II (randomised)

33: daily

Temsirolimus (two schedules) + letrozole

PR 27

Not reached

  

30: intermittent

 

CR 3, PR 27

Not reached

  

29

Letrozole

CR 7 + PR 34

9.2

   Chow et al. [84]*

III

556

Temsirolimus + letrozole

ORR 27

8.8

  

556

Letrozole

ORR 27

8.9

  1. *Study terminated due to toxicity. CR, complete response; mTOR, mammalian target of rapamycin; NR, not reported; ORR, overall response rate; PFS, progression free survival; PR, partial response; RR, response rate.